Emerging Role of Scintigraphy Using Bone-Seeking Tracers for Diagnosis of Cardiac Amyloidosis: <i>AJR</i> Expert Panel Narrative Review
Riemer H. J. A. Slart, Wengen Chen, Alwin Tubben, Hendrea S. A. Tingen, Daniel R. Davies, Martha Grogan, Ashutosh Wechalekar, M. Kittleson, Louise Thomson, Piotr J. Slomka, Kshama Wechalekar, Panithaya Chareonthaitawee
Abstract
Amyloidoses are a complex group of clinical diseases that result from progressive organ dysfunction due to extracellular protein misfolding and deposition. The two most common types of cardiac amyloidosis are transthyretin amyloidosis (ATTR) and light chain (AL) amyloidosis. The diagnosis of ATTR cardiomyopathy (ATTR-CM) is challenging due to its phenotypic similarity to other more common cardiac conditions, perceived rarity of the disease, and unfamiliarity with its diagnostic algorithms; endomyocardial biopsy was historically required for diagnosis. However, myocardial scintigraphy using bone-seeking tracers has shown high accuracy for detection of ATTR-CM and has become a key noninvasive diagnostic test for the condition, being supported by professional society guidelines and transforming prior diagnostic paradigms. This AJR Expert Panel Narrative Review describes the role of myocardial scintigraphy using bone-seeking tracers in the diagnosis of ATTR-CM. The article summarizes available tracers, acquisition techniques, interpretation and reporting considerations, diagnostic pitfalls, and gaps in the current literature. The critical need for monoclonal testing in patients with positive scintigraphy results to differentiate ATTR-CM and AL cardiac amyloidosis is highlighted. Recent updates in guideline recommendations that emphasize the importance of a qualitative visual assessment are also discussed.